NASDAQ
XENE

Xenon Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Xenon Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$37.26
Today's High:
$37.85
Open Price:
$37.37
52W Low:
$31.79
52W High:
$43.75
Prev. Close:
$37.38
Volume:
189850

Company Statistics

Market Cap.:
$2.40 billion
Book Value:
10.146
Revenue TTM:
$132000
Operating Margin TTM:
-141010.61%
Gross Profit TTM:
$-96333000
Profit Margin:
0%
Return on Assets TTM:
-15.59%
Return on Equity TTM:
-22.86%

Company Profile

Xenon Pharmaceuticals Inc had its IPO on 2014-11-05 under the ticker symbol XENE.

The company operates in the Healthcare sector and Biotechnology industry. Xenon Pharmaceuticals Inc has a staff strength of 203 employees.

Stock update

Shares of Xenon Pharmaceuticals Inc opened at $37.37 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $37.26 - $37.85, and closed at $37.27.

This is a -0.29% slip from the previous day's closing price.

A total volume of 189,850 shares were traded at the close of the day’s session.

In the last one week, shares of Xenon Pharmaceuticals Inc have slipped by -6.19%.

Xenon Pharmaceuticals Inc's Key Ratios

Xenon Pharmaceuticals Inc has a market cap of $2.40 billion, indicating a price to book ratio of 3.2172 and a price to sales ratio of 181.4446.

In the last 12-months Xenon Pharmaceuticals Inc’s revenue was $132000 with a gross profit of $-96333000 and an EBITDA of $-184304992. The EBITDA ratio measures Xenon Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Xenon Pharmaceuticals Inc’s operating margin was -141010.61% while its return on assets stood at -15.59% with a return of equity of -22.86%.

In Q2, Xenon Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Xenon Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-0.06

Its diluted EPS in the last 12-months stands at $-2.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.06. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xenon Pharmaceuticals Inc’s profitability.

Xenon Pharmaceuticals Inc stock is trading at a EV to sales ratio of 136.051 and a EV to EBITDA ratio of -16.4147. Its price to sales ratio in the trailing 12-months stood at 181.4446.

Xenon Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$684.90 million
Total Liabilities
$28.16 million
Operating Cash Flow
$0
Capital Expenditure
$2.13 million
Dividend Payout Ratio
0%

Xenon Pharmaceuticals Inc ended 2024 with $684.90 million in total assets and $0 in total liabilities. Its intangible assets were valued at $684.90 million while shareholder equity stood at $646.46 million.

Xenon Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $28.16 million in other current liabilities, 1083008000.00 in common stock, $-571935000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $64.55 million and cash and short-term investments were $539.60 million. The company’s total short-term debt was $1,223,000 while long-term debt stood at $0.

Xenon Pharmaceuticals Inc’s total current assets stands at $544.62 million while long-term investments were $112.59 million and short-term investments were $475.05 million. Its net receivables were $2.12 million compared to accounts payable of $12.03 million and inventory worth $-2123000.00.

In 2024, Xenon Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $2.13 million.

Comparatively, Xenon Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$37.27
52-Week High
$43.75
52-Week Low
$31.79
Analyst Target Price
$52.64

Xenon Pharmaceuticals Inc stock is currently trading at $37.27 per share. It touched a 52-week high of $43.75 and a 52-week low of $43.75. Analysts tracking the stock have a 12-month average target price of $52.64.

Its 50-day moving average was $37.81 and 200-day moving average was $38.13 The short ratio stood at 7.79 indicating a short percent outstanding of 0%.

Around 65.4% of the company’s stock are held by insiders while 9459.5% are held by institutions.

Frequently Asked Questions About Xenon Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Xenon Pharmaceuticals Inc is XENE

The IPO of Xenon Pharmaceuticals Inc took place on 2014-11-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$36.93
5.42
+17.2%
$3753.55
-55.3
-1.45%
$0.04
-0
-6.7%
$3.09
0.02
+0.65%
$6.48
-0.17
-2.56%
$433.35
-34.2
-7.31%
$19.13
-0.98
-4.87%
$12.01
0.35
+3%
$15.08
-0.27
-1.76%
$0.05
-0
-3.42%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Address

3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8